Home > Boards > US Listed > Medical - Drugs > Merck & Co. Inc. (MRK)

MRK 2Q18 results:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 721
Posts 108,919
Boards Moderated 16
Alias Born 09/05/02
160x600 placeholder
Correction to AstraZeneca's Lynparza Clinical Trial Article on Wednesday Dow Jones News - 8/16/2019 9:26:00 AM
LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Adv... Business Wire - 8/14/2019 6:55:00 AM
AstraZeneca's Lynparza Successful in Second Ovarian Cancer Phase 3 Study Dow Jones News - 8/14/2019 3:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/12/2019 5:14:33 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/12/2019 4:55:22 PM
BriaCell Appoints Richard J. Berman to Board of Directors GlobeNewswire Inc. - 8/12/2019 6:30:00 AM
Merck Announces Leadership Changes to Investor Relations Team Business Wire - 8/7/2019 4:39:00 PM
LYNPARZA® (olaparib) Phase 3 PROfound Trial in HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Pri... Business Wire - 8/7/2019 6:55:00 AM
AstraZeneca: Lynparza Effective in Prostate Cancer Dow Jones News - 8/7/2019 3:08:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 4:36:24 PM
Agilent Says Companion Diagnostic Gets Expanded FDA Approval Dow Jones News - 7/31/2019 3:15:00 PM
Merck: FDA Approves New Monotherapy Indication for Keytruda Dow Jones News - 7/31/2019 7:26:00 AM
FDA Approves New Monotherapy Indication for Merck’s KEYTRUDA® (pembrolizumab) Business Wire - 7/31/2019 6:45:00 AM
Merck Increases Revenue Guidance as Second-Quarter Sales Grow 12%--Update Dow Jones News - 7/30/2019 10:28:00 AM
Merck Increases Guidance for Revenue, Adjusted Earnings, Lowers GAAP Profit Expectations Dow Jones News - 7/30/2019 7:54:00 AM
Merck's Profit Rises, Sales Increase Dow Jones News - 7/30/2019 7:41:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/30/2019 6:51:31 AM
Merck Announces Second-Quarter 2019 Financial Results Business Wire - 7/30/2019 6:45:00 AM
Merck Receives Positive EU CHMP Opinion for ZERBAXA® 3g Dose (ceftolozane & tazobactam) for the Treatment of Adults with Hos... Business Wire - 7/29/2019 4:05:00 PM
Stocks to Watch: Mylan, Merck, Booz Allen, Cooper Tire, Mohawk Industries and More Dow Jones News - 7/29/2019 9:47:00 AM
Merck: Keytruda/Chemotherapy Combo Meets Primary Endpoint in Phase 3 Triple-Negative Breast Cancer Study Dow Jones News - 7/29/2019 7:56:00 AM
Merck: CHMP Backs Keytruda/Inlyta Combo in Renal Cell Carcinoma Dow Jones News - 7/29/2019 7:13:00 AM
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Pathological Complete Response ... Business Wire - 7/29/2019 6:55:00 AM
European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axit... Business Wire - 7/29/2019 6:30:00 AM
Merck to Start Phase 3 Program for Islatravir in Combination With Doravirine for HIV-1 Dow Jones News - 7/24/2019 11:56:00 AM
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist